Vizsgálati helyszín
NRC Research Institute
Orange, California 92868, Egyesült ÁllamokMég nincs intézményhez kötve
- 12futó vizsgálat
- 15lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis10 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Lezárult12 vizsgálat
- Toboroz8 vizsgálat
- Fut, nem toboroz4 vizsgálat
- Leállították3 vizsgálat
- Fő szponzor
- Biohaven Therapeutics Ltd.4 vizsgálat
- Biohaven Pharmaceuticals, Inc.3 vizsgálat
- Xenon Pharmaceuticals Inc.3 vizsgálat
- Boehringer Ingelheim2 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- és még 10
Futó vizsgálatok
Toboroz
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Contact: Tony Ortiz, Site 0151
Toboroz
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305· 2. fázis· LB Pharmaceuticals Inc.· Forrás
Contact: Abigail Parera
Toboroz
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661· 2. fázis· Supernus Pharmaceuticals, Inc.· Forrás
Contact: Gianpiera Ceresoli-Borroni, PhD
Toboroz
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397· 3. fázis· Cybin IRL Limited· Forrás
Contact: Christian Ortiz
Toboroz
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Tony Ortiz, Site 0148
Fut, nem toboroz
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Tony Ortiz, Site 0039
Fut, nem toboroz
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
NCT05889273· 2. fázis· MapLight Therapeutics· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122· Boehringer Ingelheim· Forrás
Lezárult
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Leállították
BHV-7000 Open-Label Extension Bipolar Mania Study
NCT06423794· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
NCT06126497· 2. fázis· Suven Life Sciences Limited· Forrás
Lezárult
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245· 2. fázis· MapLight Therapeutics· Forrás
Lezárult
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NCT05279313· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Lezárult
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
NCT05178316· 2. fázis· Jazz Pharmaceuticals· Forrás
Lezárult
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
NCT04846881· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
NCT04820309· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Leállították
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834· 3. fázis· Biohaven Pharmaceuticals, Inc.· Forrás
Lezárult
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143· 3. fázis· Biohaven Pharmaceuticals, Inc.· Forrás
Lezárult
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
NCT03299166· 2/3. fázis· Biohaven Pharmaceuticals, Inc.· Forrás
Leállították
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Hibát jelzek